Acute coronary syndromes

Randomized controlled trials ( RCTs ) regarding use of Ranolazine for the prevention and cardioversion of atrial fibrillation have yielded...


The landmark Dual Antiplatelet Therapy ( DAPT ) trial revealed an impressive reduction of stent thrombosis and myocardial infarction after...


When considering antiplatelet therapy for acute coronary syndrome ( ACS ), it is essential to balance benefits ( less thrombotic...


There is a paucity of data on the impact of complete revascularisation ( CR ) following percutaneous coronary intervention (...


Patients with rheumatoid arthritis and carotid artery plaques have increased risk of acute coronary syndromes. Statin treatment with low density...


Merck, known as MSD outside the United States and Canada, issued the following statement after the conclusion of a meeting...


ESC Guidelines recommended for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention ( PCI...


Osteoprotegerin ( OPG ) is promising as a predictor of adverse prognosis in patients with acute coronary syndromes and chronic...


A study has assessed the effect of Ranolazine, an anti-ischaemic agent with anti-arrhythmic properties, on the overall burden of atrial...


The phase II RADAR-PCI study has determined the feasibility of conducting percutaneous coronary intervention ( PCI ) in high-risk acute...


American Heart Association ( AHA ) and American College of Cardiology ( ACC ) have updated the guideline for the...


The results of the phase IV ATLANTIC study, which indicates that the profile of Ticagrelor ( Brilinta, Brilique ) is...


The European Medicines Agency ( EMA ), the Committee for Medicinal Products for Human Use ( CHMP ), and the...


Refinements in stent design affecting strut thickness, surface polymer, and drug release have improved clinical outcomes of drug-eluting stents. A...


p38 MAPK inhibition has potential myocardial protective effects. Researchers have assessed Losmapimod, a potent oral p38 MAPK inhibitor, in patients...


Studies have shown variation in the use of red blood cell transfusion among patients with acute coronary syndromes. There are...


A investigational IMPROVE-IT study has met its primary and all secondary composite efficacy endpoints. Treatment with Simvastatin in combination with...


IMPROVE-IT ( IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial ), was an international, multi-center, randomised, double-blind active comparator trial...


Contrast-induced acute kidney injury is an adverse outcome resulting from radiocontrast medium exposure during coronary angiography and percutaneous coronary intervention. A...


The IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine Vytorin...